摘要
目的探究HPV E6/E7 mRNA联合液基薄层细胞学检测(TCT)在宫颈癌筛查中的实施价值。方法选取2020年7月—2021年7月于该院进行宫颈癌筛查的1528例患者为研究对象,对参与研究患者均进行HPV E6/E7 mRNA、液基薄层细胞学检测(TCT),以病理切片为金标准,对比单一检测及联合检测方法筛查结果。结果经过病理切片检查,1528例患者宫颈癌筛查中,阳性例数108例,阳性率7.07%;阴性例数1420例,阴性率92.93%;联合诊断对于宫颈疾病筛查的灵敏度、特异度及诊断符合率分别为88.89%、96.34%、95.81%,较单一诊断更加理想。结论宫颈癌筛查中HPV E6/E7 mRNA联合TCT筛查效果更加理想,更加利于宫颈疾病检出,值得在临床宫颈癌疾病筛查中推广使用。
Objective To explore the implementation value of HPV E6/E7 mRNA combined with liquid-based thin-prep cytology test(TCT)in cervical cancer screening.Methods Taking 1528 cases of cervical cancer screening in the hospital from July 2020 to July 2021 as an example,all patients participating in the study had HPV E6/E7 mRNA,liquid-based thin-layer cytology(TCT).Pathological slide was the gold standard.Results of single test and Combined tests were compared.Results After pathological slide tests,there were 108 positive cases among the 1528 cases,with a positive rate of 7.07%,and 1420 negative cases,with a negative rate of 92.93%;the sensitivity,specificity and diagnostic coincidence rate of combined diagnosis for cervical disease screening were 88.89%,96.34%,and 95.81%,which were more ideal than single diagnosis.Conclusion In cervical cancer screening,HPV E6/E7 mRNA combined with TCT has a more ideal screening effect and is more conducive to the detection of cervical diseases.It is worthy of promotion and use in clinical cervical cancer screening.
作者
刘端芳
LIU Duanfang(Department of Women's Health Care,Xintai Maternal and Child Health Care Family Planning Service Center,Xintai,Shandong Province,271200 China)
出处
《系统医学》
2022年第8期160-163,共4页
Systems Medicine
